1803079-49-3: Linagliptin N-Acetyl Impurity
Linagliptin N-Acetyl Impurity (CAS No: 1803079-49-3) Or (R)-N-(1-(7-(But-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)piperidin-3-yl)acetamide,Linagliptin is a DPP-4 inhibitor, developed by Boehringer Ingelheim, which is used for the treatment of type II diabetes.
Additional information on CAS 1803079-49-3
VL870004
1803079-49-3
C₂₇H₃₀N₈O₃
514.58
Linagliptin
(R)-N-(1-(7-(But-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-2, 6-dioxo-2, 3, 6, 7-tetrahydro-1H-purin-8-yl)piperidin-3-yl)acetamide
(R)-N-(1-(7-(But-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-2, 6-dioxo-2, 3, 6, 7-tetrahydro-1H-purin-8-yl)piperidin-3-yl)acetamide; Linagliptin N-Acetyl Impurity
Sci-Hub, LC–MS/MS and NMR Characterization of Key Impurities in Linagliptin and Pramipexole, 10.1080/10826076.2015.1087861. (2015). Retrieved December 17, 2021, from Hkvisa.net website: https://sci-hub.hkvisa.net/10.1080/10826076.2015.1087861
In-stock
